{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:12:23Z","timestamp":1760573543458,"version":"build-2065373602"},"reference-count":73,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780443297229"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.irn.2025.04.019","type":"book-chapter","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T11:05:29Z","timestamp":1758020729000},"page":"161-178","source":"Crossref","is-referenced-by-count":0,"title":["Measuring treatment related side effect burden in myasthenia gravis"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.irn.2025.04.019_bib1","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): A multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"The Lancet Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12883-019-1573-2","article-title":"Understanding side effects of therapy for myasthenia gravis and their impact on daily life","volume":"19","author":"Bacci","year":"2019","journal-title":"BMC Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib3","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1212\/WNL.0000000000002971","article-title":"Development and validation of the myasthenia gravis impairment index","volume":"87","author":"Barnett","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib4","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1212\/WNL.0000000000004676","article-title":"Myasthenia gravis impairment index: Responsiveness, meaningful change, and relative efficiency","volume":"89","author":"Barnett","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib5","first-page":"307","article-title":"The costs of adverse drug events in hospitalized patients","volume":"277","author":"Bates","year":"1997","journal-title":"Adverse Drug Events Prevention Study Group. JAMA: the Journal of the American Medical Association"},{"key":"10.1016\/bs.irn.2025.04.019_bib6","first-page":"70","article-title":"Assessing glucocorticoid associated toxicity in myasthenia gravis using the glucocorticoid toxicty index (GTI)","author":"Beaudin","year":"2024","journal-title":"Muscle and Nerve"},{"key":"10.1016\/bs.irn.2025.04.019_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/mus.27742","article-title":"The best and worst of times in therapy development for myasthenia gravis","volume":"67","author":"Benatar","year":"2023","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.019_bib8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): A randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"The Lancet Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib9","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG composite: A valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.21883","article-title":"The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis","volume":"43","author":"Burns","year":"2011","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.019_bib11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/mus.25198","article-title":"International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r","volume":"54","author":"Burns","year":"2016","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.019_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/mus.24953","article-title":"The best of both worlds: Using patient-reported plus physician-scored measures during the evaluation of myasthenia gravis","volume":"53","author":"Burns","year":"2016","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.019_bib13","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1212\/WNL.0000000000002972","article-title":"Using disease-specific, patient-reported measures in everyday clinic","volume":"87","author":"Burns","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib14","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a015677","article-title":"Cancer in the transplant recipient","volume":"3","author":"Chapman","year":"2013","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"10.1016\/bs.irn.2025.04.019_bib15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jama.1997.03540280039031","article-title":"Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality","volume":"277","author":"Classen","year":"1997","journal-title":"JAMA: the Journal of the American Medical Association"},{"key":"10.1016\/bs.irn.2025.04.019_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mus.27988","article-title":"Quantifying adverse events: The burden is on us!","volume":"69","author":"Claytor","year":"2024","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.019_bib17","unstructured":"Control CfD. Clinical guidance for managing meningococcal disease risk in patients receiving complement inhibitor therapy [online]. Available at: https:\/\/www.cdc.gov\/meningococcal\/hcp\/clinical-guidance\/complement-inhibitor.html. (Accessed 19 November 2024)."},{"key":"10.1016\/bs.irn.2025.04.019_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.nmd.2024.03.010","article-title":"Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravis","volume":"38","author":"Dodd","year":"2024","journal-title":"Neuromuscular Disorders: NMD"},{"key":"10.1016\/bs.irn.2025.04.019_bib19","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/mus.27393","article-title":"Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients >\/=65 years old","volume":"64","author":"Doughty","year":"2021","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.019_bib20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.mcna.2016.01.006","article-title":"De novo malignancies after transplantation: Risk and surveillance strategies","volume":"100","author":"Doycheva","year":"2016","journal-title":"The Medical Clinics of North America"},{"key":"10.1016\/bs.irn.2025.04.019_bib21","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1749-6632.1998.tb11011.x","article-title":"Risk of cancer in patients with myasthenia gravis","volume":"841","author":"Evoli","year":"1998","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/bs.irn.2025.04.019_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11060-004-5676-1","article-title":"Primary CNS lymphoma in myasthenic on long-term azathioprine","volume":"74","author":"Finelli","year":"2005","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/bs.irn.2025.04.019_bib23","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.34067\/KID.0000502021","article-title":"Glucocorticoid therapy in ANCA vasculitis: Using the glucocorticoid toxicity index as an outcome measure","volume":"2","author":"Floyd","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/bs.irn.2025.04.019_bib24","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1007\/s00415-024-12293-5","article-title":"Real-world experience with efgartigimod in patients with myasthenia gravis","volume":"271","author":"Fuchs","year":"2024","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/mus.27260","article-title":"Telemedicine visits in myasthenia gravis: Expert guidance and the myasthenia gravis core exam (MG-CE)","author":"Guidon","year":"2021","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.019_bib26","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/mus.22212","article-title":"Cost analysis of myasthenia gravis from a large U.S. insurance database","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.019_bib27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/mus.28038","article-title":"How should newer therapeutic agents be incorporated into the treatment of patients with myasthenia gravis?","volume":"69","author":"Gwathmey","year":"2024","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.019_bib28","first-page":"121","article-title":"Measuring adverse event burden in myasthenia gravis: Retrospective Validation of the adverse event unit (AEU) with MGTX trial data","author":"Hehir","year":"2023","journal-title":"Neuromuscular Study Group Annual Meeting. Orlando, FL: RRNMF Neuromuscular Journal"},{"key":"10.1016\/bs.irn.2025.04.019_bib29","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1212\/CON.0000000000001161","article-title":"Diagnosis and management of myasthenia gravis","volume":"28","author":"Hehir","year":"2022","journal-title":"Continuum (Minneap Minn"},{"key":"10.1016\/bs.irn.2025.04.019_bib30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: Outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.019_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262109","article-title":"The adverse event unit (AEU): A novel metric to measure the burden of treatment adverse events","volume":"17","author":"Hehir","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/bs.irn.2025.04.019_bib32","article-title":"Measuring treatment adverse event burden in myasthenia gravis: Single-center prospective evaluation utilizing the adverse event unit (AEU)","author":"Hehir","year":"2023","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.019_bib33","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/mus.26850","article-title":"Myasthenia gravis patient and physician opinions about immunosuppressant reduction","volume":"61","author":"Hehir","year":"2020","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.019_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241243186","article-title":"Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: Interim analysis of the RAISE-XT open-label extension study","volume":"17","author":"Howard","year":"2024","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1016\/bs.irn.2025.04.019_bib35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): A randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"The Lancet Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib36","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): A multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"The Lancet Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib37","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"The Lancet Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00378","article-title":"Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)","author":"Howard","year":"2024","journal-title":"Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics"},{"key":"10.1016\/bs.irn.2025.04.019_bib39","unstructured":"Institute N.C. (2024). Common terminology criteria for adverse events (CTCAE) [online]. Available at: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_60. (Accessed 12 March 2024)."},{"key":"10.1016\/bs.irn.2025.04.019_bib40","unstructured":"Institute NC. (2009). Common Terminology Criteria for Adverse Events (CTCAE) [online]. Available at: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_60. Accessed 12-3-2024."},{"key":"10.1016\/bs.irn.2025.04.019_bib41","doi-asserted-by":"crossref","first-page":"e933296","DOI":"10.12659\/MSM.933296","article-title":"Adverse side effects associated with corticosteroid therapy: A study in 39 patients with generalized myasthenia gravis","volume":"27","author":"Johnson","year":"2021","journal-title":"Medical Science Monitor: International Medical Journal of Experimental and Clinical Research"},{"key":"10.1016\/bs.irn.2025.04.019_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124356","article-title":"Missing dosages and neuroleptic usage may prolong length of stay in hospitalized Parkinson's disease patients","volume":"10","author":"Martinez-Ramirez","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/bs.irn.2025.04.019_bib43","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.5692\/clinicalneurol.52.1043","article-title":"[The MG-QOL15 Japanese version: Validation and associations with clinical factors","volume":"52","author":"Masuda","year":"2012","journal-title":"Rinsho Shinkeigaku = Clinical Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.396","article-title":"Nonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients","volume":"5","author":"McGurgan","year":"2015","journal-title":"Brain and Behavior"},{"key":"10.1016\/bs.irn.2025.04.019_bib45","unstructured":"MedDRA. Medical Dictonary for Regulatory Activities. International medical terminology developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [online]. Available at: https:\/\/www.meddra.org\/. (Accessed 12 March 2024)."},{"key":"10.1016\/bs.irn.2025.04.019_bib46","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: Results from the phase 3 CHAMPION MG open-label extension","volume":"270","author":"Meisel","year":"2023","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib47","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","article-title":"Development of a glucocorticoid toxicity index (GTI) using multicriteria decision analysis","volume":"76","author":"Miloslavsky","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/bs.irn.2025.04.019_bib48","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJMp1114866","article-title":"Preparing for precision medicine","volume":"366","author":"Mirnezami","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2025.04.019_bib49","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.019_bib50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/CND.0000000000000156","article-title":"Outcome measures in myasthenia gravis: Incorporation into clinical practice","volume":"18","author":"Muppidi","year":"2017","journal-title":"Journal of Clinical Neuromuscular Disease"},{"key":"10.1016\/bs.irn.2025.04.019_bib51","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1749-6632.2012.06817.x","article-title":"The myasthenia gravis--specific activities of daily living profile","volume":"1274","author":"Muppidi","year":"2012","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/bs.irn.2025.04.019_bib52","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1474-4422(24)00028-0","article-title":"Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): A prospective cohort study","volume":"23","author":"Narayanaswami","year":"2024","journal-title":"The Lancet Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib53","first-page":"e2182","article-title":"B-cell targeted treatment in myasthenia gravis (BeatMG): A phase 2 trial of rituximab in myasthenia gravis: Topline results","volume":"90","author":"Nowak","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib54","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia gravis study group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib55","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: Report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib56","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: The RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib57","unstructured":"Quality AfHRa. (2001). Reducing and preventing adverse drug events to decrease hospital costs. https:\/\/archiveahrqgov\/research\/findings\/factsheets\/errors-safety\/aderia\/adehtml."},{"key":"10.1016\/bs.irn.2025.04.019_bib58","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1468-1331.2006.01382.x","article-title":"Safety of long-term combined immunosuppressive treatment in myasthenia gravis--analysis of adverse effects of 163 patients","volume":"13","author":"Rozsa","year":"2006","journal-title":"European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies"},{"key":"10.1016\/bs.irn.2025.04.019_bib59","first-page":"70","article-title":"Chronic steroid toxicity in adults with myasthenia gravis in the United States based on electronic health records","author":"Ruck","year":"2024","journal-title":"Muscle and Nerve"},{"key":"10.1016\/bs.irn.2025.04.019_bib60","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0002-9343(94)90131-7","article-title":"Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events","volume":"96","author":"Saag","year":"1994","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/bs.irn.2025.04.019_bib61","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00415-009-5256-6","article-title":"Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy","volume":"257","author":"Schepelmann","year":"2010","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.019_bib63","article-title":"The cost of rare diseases is threatening the U.S. Health care system","author":"Smith","year":"2017","journal-title":"Harvard Business Review"},{"key":"10.1016\/bs.irn.2025.04.019_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152010","article-title":"The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time","volume":"55","author":"Stone","year":"2022","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1016\/bs.irn.2025.04.019_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: A systematic review","author":"Tandan","year":"2017","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.019_bib66","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/ncponc1071","article-title":"Methotrexate-associated mantle-cell lymphoma in an elderly man with myasthenia gravis","volume":"5","author":"Tran","year":"2008","journal-title":"Nature Clinical Practice. Oncology"},{"key":"10.1016\/bs.irn.2025.04.019_bib67","article-title":"Eculizumab and efgartigamod for the treatment of myasthenia gravis: Effectiveness and value; final report","author":"Trice","year":"2021","journal-title":"Institute for Clinical and Economic Review"},{"key":"10.1016\/bs.irn.2025.04.019_bib68","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/mus.25397","article-title":"Early fast-acting treatment strategy against generalized myasthenia gravis","volume":"55","author":"Utsugisawa","year":"2017","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.019_bib69","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/mus.24213","article-title":"Health-related quality-of-life and treatment targets in myasthenia gravis","volume":"50","author":"Utsugisawa","year":"2014","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.019_bib70","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1111\/ene.14730","article-title":"Cancer in myasthenia gravis subtypes in relation to immunosuppressive treatment and acetylcholine receptor antibodies: A Swedish nationwide register study","volume":"28","author":"Verwijst","year":"2021","journal-title":"European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies"},{"key":"10.1016\/bs.irn.2025.04.019_bib71","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/bs.irn.2025.04.019_bib72","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2025.04.019_bib73","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.nmd.2013.11.007","article-title":"Excessive risk of cancer and in particular lymphoid malignancy in myasthenia gravis patients: A population-based cohort study","volume":"24","author":"Yeh","year":"2014","journal-title":"Neuromuscular Disorders: NMD"}],"container-title":["International Review of Neurobiology","Myasthenia Gravis, Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T03:59:04Z","timestamp":1760500744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774225000340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443297229"],"references-count":73,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2025.04.019","relation":{},"ISSN":["0074-7742"],"issn-type":[{"type":"print","value":"0074-7742"}],"subject":[],"published":{"date-parts":[[2025]]}}}